| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b75d73e09e4f6448a86285fc5254e5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2016-05-20^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe67d0d5e1bd3ddda8e807de337b066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_814ad7500c4dd4a3645a549b77b3b3b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a34c34ac426c2690d8a142aeea59520
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6f4be7fcb6f24bd1f95fe185b30d857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca27d48cb6d36b33bc92856c4d79f55b |
| publicationDate |
2016-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016187571-A2 |
| titleOfInvention |
Her2 immunotoxins and methods of using the same |
| abstract |
The present invention relates to methods for preventing or treating cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell and; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of cancer using a recombinant immunotoxin comprising an anti-HER2/neu antibody or antibody fragment that is fused to a deimmunized bouganin toxin. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer. |
| priorityDate |
2015-05-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |